| 
				全民健康保險藥品給付規定 / 健保碼及健保價 | 
		 
		
			| 
				See related Maxipime powd for inj[邁菌平 乾粉注射劑] information | 
		 
		
			| 
				  | 
		 
		
			| 
				製造商 | 
			
				Bristol-Myers Squibb | 
		 
		
			| 
				代理/經銷商 | 
			
				Bristol-Myers Squibb | 
		 
		
			| 
				成份 | 
			
				Cefepime | 
		 
		
			| 
				適應症 | 
			
				In adults: Lower respiratory tract infections (including pneumonia & bronchitis), UTI (both complicated, including pyelonephritis & uncomplicated), skin & skin structure infections, intra-abdominal infections (including peritonitis & biliary tract infections), gynecologic infections, septicemia, empiric treatment in febrile neutropenic patients. In children: Pneumonia, UTI (both complicated, including pyelonephritis & uncomplicated), skin & skin structure infections, intra-abdominal infections (including peritonitis & biliary tract infections), septicemia, empiric treatment in febrile neutropenia. | 
		 
		
			| 
				用量 | 
			
				Adult & children > 40 kg with normal renal function Mild to moderate UTI 0.5-1 g IM/IV 12 hourly. Mild to moderate infections (other than UTI) 1 g IM/IV 12 hourly. Severe infections 2 g IV 12 hourly. Very severe or life-threatening infections 2 g IV 8 hourly. Usual duration of therapy: 7-10 days; more severe infections may require longer treatment. Children 1 month-12 year with normal renal function & body weight ≤ 40 kg Pneumonia, UTI, skin & skin structure infections 50 mg/kg 12 hourly for 10 days. For more severe infections, the doses can be given 8 hourly. Septicemia & empiric treatment of febrile neutropenia 50 mg/kg 8 hourly for 7-10 days. | 
		 
		
			| 
				過量 | 
			
				View Maxipime[邁菌平] overdosage for action to be taken in the event of an overdose. | 
		 
		
			| 
				美國食品藥物管理局之懷孕等級 | 
			
				
				Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). | 
		 
		
			| 
				禁忌 | 
			
				Hypersensitivity to cephalosporins, penicillins or other β-lactam antibiotics. | 
		 
		
			| 
				注意事項 | 
			
				Hypersensitivity, pseudomembranous colitis & superinfection may occur. Discontinue therapy if allergic reaction occurs. Pregnancy, lactation. | 
		 
		
			| 
				不良反應 | 
			
				GI disturbances (diarrhoea, nausea, vomiting). Hypersensitivity. CV, respiratory & CNS disorders. Vaginitis. 
				View ADR Monitoring Website[參閱藥物不良反應監測表格] | 
		 
		
			| 
				副作用 | 
			
				View Maxipime[邁菌平] side effects | 
		 
		
			| 
				交互作用 | 
			
				[Click for Maxipime[邁菌平] detailed prescribing infomation] 
				View more drug interactions with Maxipime[邁菌平] | 
		 
		
			| 
				使用上注意 | 
			
				For caution against possible variation of physical aspect of medicine... click to view Maxipime[邁菌平] detailed prescribing infomation | 
		 
		
			| 
				儲存 | 
			
				View Maxipime[邁菌平] storage conditions for details to ensure optimal shelf-life. | 
		 
		
			| 
				描述 | 
			
				View Maxipime[邁菌平] description for details of the chemical structure and excipients (inactive components). | 
		 
		
			| 
				作用 | 
			
				View Maxipime[邁菌平] mechanism of action for pharmacodynamics and pharmacokinetics details. | 
		 
	
 
 
	
		
			| 
				本商品之市售規格 | 
		 
		
			
				
					
						
							| 
								劑型 | 
							
								包裝 | 
							
								圖片 | 
						 
						
							| 
								Maxipime 乾粉注射劑  | 
							
								
									
										
											| 
												Maxipime 1 g x 1's | 
											
												  | 
										 
										
											| 
												Maxipime 500 mg x 1's | 
											
												  | 
										 
									
								 
							 | 
						 
					
				 
				 | 
		 
		
			
				
					
						
							
								
									
										
											| 
												Manufacturer: | 
											
												Bristol-Myers Squibb | 
										 
										
											| 
												Distributor: | 
											
												Bristol-Myers Squibb | 
										 
									
								 
							 | 
						 
					
				 
			 | 
		 
	
 
 |